Screening for lipid disorders in adults
- Sandeep Vijan, MD
Sandeep Vijan, MD
- Professor of Internal Medicine
- University of Michigan
- Section Editors
- Mason W Freeman, MD
Mason W Freeman, MD
- Section Editor — Lipids
- Professor of Medicine
- Harvard Medical School
- Joann G Elmore, MD, MPH
Joann G Elmore, MD, MPH
- Editor-in-Chief — Primary Care (Adult)
- Section Editor — General Medicine
- Professor of Medicine, Adjunct Professor of Epidemiology
- University of Washington School of Medicine
- Deputy Editors
- Howard Libman, MD
Howard Libman, MD
- Deputy Editor — Primary Care (Adult)
- Professor of Medicine, Emeritus
- Harvard Medical School
- Gordon M Saperia, MD, FACC
Gordon M Saperia, MD, FACC
- Senior Deputy Editor — UpToDate
- Deputy Editor — Cardiovascular Medicine
- Assistant Professor of Medicine
- Tufts University School of Medicine
This topic addresses issues surrounding screening for lipid disorders in an adult primary prevention setting. The lipid profile and its components (total cholesterol, low density lipoprotein cholesterol, high density cholesterol, and triglycerides) are some of the most commonly ordered laboratory tests in clinical practice. The most common indication for this test (or its components) is for aiding the process of determining cardiovascular disease event risk. Other indications for these tests include the following:
●Identifying patients who are at high risk for a lipid abnormality due to a family history of genetic disorder, such as familial hypercholesterolemia; this has been referred to as "reverse cascade screening." (See "Inherited disorders of LDL-cholesterol metabolism".)
●Identifying the cause of another clinical problem such as pancreatitis.
●Managing patients with established atherosclerotic cardiovascular disease.
●Evaluating the efficacy of and/or adherence with lipid lowering therapy and lifestyle modification.
- Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 2010; 45:907.
- Chou R, Dana T, Blazina I, et al. Screening for Dyslipidemia in Younger Adults: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med 2016; 165:560.
- http://www.who.int/gho/ncd/risk_factors/cholesterol_mean_text/en/ (Accessed on September 28, 2016).
- Silverman MG, Ference BA, Im K, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016; 316:1289.
- Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011; 123:2292.
- D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286:180.
- Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol 1988; 4 Suppl A:5A.
- Arsenault BJ, Boekholdt SM, Kastelein JJ. Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol 2011; 8:197.
- Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298:776.
- Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993.
- Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307:1302.
- Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005; 294:1773.
- Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S49.